Clinical trials: Stage II Skin Cancer
Uveal Melanoma, Ocular Melanoma
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma.
- Trial name
- OCULE-01 (NCT06717126)
- Testing
- roginolisib, Investigator choice of standard therapy
- Where
- 16 sites in Italy, Spain and 1 more
- Volunteers
- 85 people
- Sponsor
- iOnctura
Breast Neoplasms
A Study of E7389 in Advanced/Metastatic Breast Cancer Patients
The purpose of this study is to determine if E7389 is a safe and effective treatment for advanced/metastatic breast cancer.
- Trial name
- NCT00097721
- Testing
- E7389
- Where
- 16 sites in United States
- Volunteers
- 104 people
- Sponsor
- Eisai Inc.
Solid Tumor, Adult, Non-small Cell Lung Cancer
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
- Trial name
- NCT04913285
- Testing
- KIN-2787, KIN-2787 and binimetinib
- Where
- 48 sites in United States, Australia and 5 more
- Volunteers
- 400 people
- Sponsor
- Pierre Fabre Medicament
Malignant Melanoma
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)
This study was conducted to compare survival using pembrolizumab (SCH 900475, MK-3475) or standard chemotherapy in participants with advanced melanoma (MEL) who had progressed after prior therapy.
- Trial name
- NCT01704287
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Volunteers
- 540 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Breast Cancer
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).
- Trial name
- NCT00303108
- Testing
- Pegylated liposomal doxorubicin, Carboplatin, trastuzumab
- Where
- 57 sites in United States
- Volunteers
- 136 people
- Sponsor
- US Oncology Research
Stage IV (Metastatic) Breast Cancer
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
The purpose of this study is to: 1) determine the optimal tolerated dose of ABI-007 and vinorelbine, given concurrently on a weekly basis, in the absence of planned growth factor support with granulocyte colony-stimulating factor…
- Trial name
- NCT00140140
- Testing
- ABI-007, vinorelbine, Trastuzumab
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Celgene
Malignant Melanoma, Neoplasm Metastasis
Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma
This is a research study to look at the ways in which a treatment called INGN241 can kill melanoma cells or help the patient's immune system kill melanoma cells.
- Trial name
- NCT00116363
- Testing
- investigational drug INGN 241
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Introgen Therapeutics
Breast Cancer
A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer
This randomized study will assess the effect of adding bevacizumab to trastuzumab plus docetaxel in neoadjuvant therapy in participants with early stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
- Trial name
- AVATAXHER (NCT01142778)
- Testing
- Bevacizumab, Docetaxel, Trastuzumab
- Where
- 28 sites in France
- Volunteers
- 152 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms, Invasive Breast Cancer
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer.
- Conditions
- Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- EVANGELINE (NCT05607004)
- Testing
- (Z)-endoxifen, goserelin
- Where
- 14 sites in United States
- Volunteers
- 87 people
- Sponsor
- Atossa Therapeutics, Inc.
Breast Cancer
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
The purpose of this study is to evaluate the Safety and Efficacy of Neoadjuvant study of DV in combination Toripalimab i or sequence chemotherapy in HR-negative, HER2 low-expressing Breast Cancer
- Trial name
- NCT06227117
- Testing
- Disitamab Vedotin Injection （18 weeks）, Toripalimab （18weeks）, Carboplatin
- Where
- 5 sites in China
- Volunteers
- 120 people
- Sponsor
- RemeGen Co., Ltd.
Breast Neoplasms
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)
The purpose of the study is to evaluate the efficacy of the triplet of ridaforolimus, dalotuzumab and exemestane compared to the combination of ridaforolimus and exemestane in post-menopausal participants with breast cancer.
- Trial name
- NCT01605396
- Testing
- Ridaforolimus, Dalotuzumab, Exemestane
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters
RATIONALE: Collecting blood samples and health information from patients with invasive breast cancer and from their brothers and sisters over time may help the study of cancer in the future.
- Trial name
- NCT00445562
- Testing
- biologic sample preservation procedure, informational intervention
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- GenBasix Incorporated
Malignant Melanoma
A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases
This open-label, single-arm, multicenter study will evaluate the efficacy and safety in participants with metastatic melanoma who developed brain metastases.
- Trial name
- NCT01378975
- Testing
- Vemurafenib
- Where
- 33 sites in United States, Australia and 8 more
- Volunteers
- 146 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
To assess whether adding LCL161 to weekly paclitaxel enhances the efficacy of paclitaxel in women with triple negative breast cancer whose tumors are positive for a defined pattern of gene expression
- Trial name
- NCT01617668
- Testing
- LCL161, paclitaxel
- Where
- 50 sites in United States, Australia and 10 more
- Volunteers
- 209 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients
This is a 2-arm, randomized, double-blind, placebo-controlled study aiming to determine the efficacy and safety of DLBS1425 in combination with anthracyclin-based regimen as a neoadjuvant therapy in subjects with previously…
- Trial name
- NCT01433562
- Testing
- DLBS1425
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- Dexa Medica Group
Breast Cancer
Study of E7389 for Advanced or Metastatic Breast Cancer
The purpose of this study (E7389-J081-224; hereafter referred to as Study 224) is to evaluate the safety of patients who continue to receive E7389 after completing the Phase II clinical study (E7389-J081-221; hereafter referred…
- Trial name
- NCT00965523
- Testing
- Eribulin Mesylate
- Where
- 5 sites in Japan
- Volunteers
- 81 people
- Sponsor
- Eisai Co., Ltd.
Breast Cancer
Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00005635
- Testing
- trastuzumab, paclitaxel
- Where
- United States
- Sponsor
- Genentech, Inc.
Postmenopausal Women, Locally Advanced Metastatic Breast Cancer
Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
This was a multi-center, Israeli phase II open label study evaluating treatment with RAD001 (10 mg daily) combined with letrozole (2.5 mg daily) in postmenopausal women after recurrence or progression on Tamoxifen, Anastrozole or…
- Conditions
- Postmenopausal Women, Locally Advanced Metastatic Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT01231659
- Testing
- Everolimus, Letrozole
- Where
- 7 sites in Israel
- Volunteers
- 72 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer
LEP-ETU is a novel, proprietary delivery system of paclitaxel developed by NeoPharm, Inc. Paclitaxel (currently marketed as Taxol) is an anti-microtubular network agent and is active in a broad spectrum of malignancies.
- Trial name
- NCT01190982
- Testing
- LEP-ETU
- Where
- 3 sites in India
- Volunteers
- 70 people
- Sponsor
- INSYS Therapeutics Inc
Breast Cancer
Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
The study includes Phase I dose escalation and expansion and Phase II combination therapy. It uses a multicenter, open-label, non-randomized design to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy…
- Trial name
- NCT07697443
- Testing
- TQB3126
- Where
- 6 sites in China
- Volunteers
- 300 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.